Direxion Daily S&P Biotech Bear 3X ETF
LABD
3 hedge funds and large institutions have $3.25M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2015 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.03% more ownership
Funds ownership: 0% → 0.03% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$2.5M |
| 2 |
VF
Virtu Financial
New York
|
+$857K |
| 3 |
Jane Street
New York
|
+$357K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citigroup
New York
| $2.2M | +$2.5M | +35 | New |
|
|
VF
2
Virtu Financial
New York
| $755K | +$857K | +12 | New |
|
|
3
Jane Street
New York
| $296K | +$357K | +5 | New |
|
LABD Hedge Fund Activity: Q2 2015 in Review
3 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q2 2015, worth a combined $3.25M.
Buyers outnumbered sellers: 3 funds opened new LABD positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citigroup, opening a new position worth an estimated $2.5M.
- 3 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $3.25M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q2 2015.
- 3 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q2 2015 and 0 closed out, a net change of +3 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q2 2015 was Citigroup, an estimated $2.5M added.
Based on aggregated 13F filings for Q2 2015.